We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01617642
Recruitment Status : Active, not recruiting
First Posted : June 12, 2012
Last Update Posted : January 23, 2023
The Royal Norwegian Ministry of Health
Information provided by (Responsible Party):
Nordlandssykehuset HF

Brief Summary:
Acute intermittent porphyria (AIP) is an autosomal dominant inherited disease, which is relatively prevalent in northern Norway with a total of around 90 patients. This provides us with a special opportunity to study AIP. AIP is caused by a mutation in the porphobilinogen deaminase, an enzyme in the haem synthesis. AIP presents symptoms, particularly among fertile women and older men. Typical symptoms are abdominal pain and dark red urine, nausea, vomiting, constipation, muscle weakness and nerve damage including paraesthesia and even paresis. This is known as symptomatic or manifest AIP (MAIP). Others do not display symptoms, so-called latent AIP (LAIP). AIP attacks may be triggered by a host of medicaments which affect the haem synthesis, infections, alcohol and stress. Treatments of manifestations include high sugar intake (4 sugar lumps/hour), alternatively administer glucose and Normosang (synthetic haem arginate) by intravenous injection and removing triggering factors. Diet, glucose intake, dental health and inflammatory parameters will be examined. This study can provide new knowledge about why only some people develop symptoms of AIP. Main hypothesis: There are differences in the diet, iron status, inflammation and glucose metabolism of the MAIP group vs. the LAIP group and the control group.

Condition or disease
Acute Intermittent Porphyria

Detailed Description:

In a group of people with proven acute intermittent porphyria (AIP) mutation, some will remain asymptomatic, while others have repeated periods of porphyria symptoms. Glucose inhibits ALA synthetase (ALAS), the first rate-limiting enzyme in the haem synthesis. Studies of individual patients point to the fact that increased glucose and/or fructose content in the diet inhibits porphyria attacks. A high sugar intake can reduce the disease activity in patients with AIP. The diet and related biomarkers of those with latent and manifest AIP will therefore be mapped to explain why some have latent and others have manifest acute intermittent porphyria. Other studies point to the fact that people with manifest AIP who have later developed diabetes type 2 no longer have porphyria symptoms. Dental health will also be examined.

Inflammation also affects the haem synthesis. Infections and/or inflammation are known to trigger AIP attacks. The disease activity in patients with acute intermittent porphyria in relation to inflammatory status, iron status, glucose metabolism and diet will therefore be examined.

The iron metabolism is interesting to study because it is believed that the overstimulation of the haem synthesis is what triggers porphyria attacks. Haem consists of iron and protoporphyrin IX, and it is therefore possible that iron supplements in cases of iron deficiency can induce increased haem synthesis and by doing so trigger and/or aggravate AIP.

Kidney failure is a serious secondary complication in some patients with MAIP. Protein markers for kidney injury in urine will be examined.

Layout table for study information
Study Type : Observational
Actual Enrollment : 100 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)
Actual Study Start Date : July 1, 2012
Estimated Primary Completion Date : December 31, 2023
Estimated Study Completion Date : December 31, 2023

Control group
Healthy control group, matched for age and gender
Acute intermittent porphyria
Patients with acute intermittent porphyria.

Primary Outcome Measures :
  1. Blood pressure [ Time Frame: Within 2 months after inclusion ]
    Resting systolic and diastolic blood pressure, a number of inflammatory parameters, serum markers for iron status and inflammation

  2. Diet registration [ Time Frame: Within 2 months after inclusion ]
    Dietary registration during one week

  3. Iron status [ Time Frame: Within 2 months after inclusion ]
    Blood samples for evaluation of iron status

  4. Inflammatory status [ Time Frame: Within 2 months after inclusion ]
    Blood samples (cytokines etc) for evaluation of inflammation

Secondary Outcome Measures :
  1. Dental health [ Time Frame: Within two months after inclusion ]
    Evaluate dental health through clinical examination

Biospecimen Retention:   Samples With DNA
Serum and plasma from 50 cases With acute intermittent porphyria and age, sex and place of 50 recidence matched controls. Urine samples. Pax tubes for RNA/DNA samples.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

The group of patients with acute intermittent porphyria will be recruited from primary care clinics and patient organizations.

The control group will be selected randomly from the same geographical area, matched for gender and age


Inclusion Criteria:

  • Diagnosed acute intermittent porphyria

Exclusion Criteria:

  • Regulatory use of antiinflammatory drugs including steroids and NSAIDS
  • Lacking consent competence

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01617642

Layout table for location information
Nordlandssykehuset HF
Bodø, Nordland, Norway, N-8092
Sponsors and Collaborators
Nordlandssykehuset HF
The Royal Norwegian Ministry of Health
Layout table for investigator information
Principal Investigator: Ole L Brekke, MD, PhD University of Tromsø, Norway
Layout table for additonal information
Responsible Party: Nordlandssykehuset HF
ClinicalTrials.gov Identifier: NCT01617642    
Other Study ID Numbers: 2011/2197/REK
ID/7462 SFP 1068-12 ( Other Grant/Funding Number: Northern Norway Regional Health Authority )
First Posted: June 12, 2012    Key Record Dates
Last Update Posted: January 23, 2023
Last Verified: January 2023
Keywords provided by Nordlandssykehuset HF:
Iron status
Additional relevant MeSH terms:
Layout table for MeSH terms
Porphyria, Acute Intermittent
Porphyria, Erythropoietic
Pathologic Processes
Metabolic Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Porphyrias, Hepatic
Liver Diseases
Digestive System Diseases